Document is current
Any future updates will be listed below
-
Authors
Alarcón-Vila, Cristina
Hurtado-Navarro, Laura
Mateo, Sandra V
Peñín-Franch, Alejandro
Martínez, Carlos M https://orcid.org/0000-0003-3307-1326
Molina-López, Cristina https://orcid.org/0000-0002-4359-8140
Baños, María C
Gómez, Ana I
Gómez-Román, Javier
Baroja-Mazo, Alberto
Arostegui, Juan I
Palmou-Fontana, Natalia
Martínez-García, Juan J https://orcid.org/0000-0003-2997-8419
Pelegrin, Pablo https://orcid.org/0000-0002-9688-1804
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (PID2020-116709RB-I00)
Ministerio de Ciencia e Innovación (CNS2022-135101)
Fundación Séneca (21897/PI/22)
European Union «Next Generation EU/PRTR» (PID2023-147531OB-I00)
- License Information
-
More Information
Article History
Received: 23 September 2024
Revised: 6 November 2024
Accepted: 7 November 2024
First Online: 5 December 2024
Disclosure and competing interests statement
: PP and JJMG declare that they are inventors in a patent filed on March 2020 by the Fundación para la Formación e Investigación Sanitaria de la Región de Murcia (PCT/EP2020/056729) for a method to identify NLRP3-immunocompromised sepsis patients. PP, LH-N, JJMG and ABM are co-founders of Viva in vitro diagnostics SL, but declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The remaining authors declare no competing interests.
